On October 24, the U.S. Food and Drug Administration (FDA) issued a news release announcing its approval of XOFLUZATM (baloxavir marboxil) for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours. The FDA’s Commissioner, Scott Gottlieb, M.D., stated, “This is […]

Go to Original Post